Vodis Pharmaceuticals, Inc is a Canadian company that is considered one of the country’s leaders in medical marijuana. With award-winning grow teams, the company is awaiting an inspection by Health Canada to obtain its marijuana license under the Marihuana for Medical Purposes Regulations (MMPR). Among its most recent developments is the formation of its US subsidiary to penetrate the market through Washington State.
The company was founded in 2011. It first explored several mineral properties in British Columbia, operating as Southbridge Resources Corp. In 2014, it fully committed to the pharma industry by changing its name to Vodis Pharmaceuticals, Inc and acquiring its subsidiary company Vodis Innovative Pharmaceuticals, Inc.
Vodis Pharmaceuticals is now traded in the Canadian Securities Exchange under the symbol VP. Its market cap is at CAD 18.93 M.
The company’s current product line is comprised of 25 different strains of medicinal cannabis. These are categorized into Sativa, Indica, and Hybrid groups. The subsidiary Vodis Innovative Pharmaceuticals handles these products and sells them through the company website. As of October 2014, its online selling is temporarily halted as Vodis awaits inspection.
Upon obtaining its MMPR license, Vodis Pharmaceuticals will be allowed to produce a monthly total of 150 to 200 pounds of medicinal cannabis in Canada. The company already has a 12,000-square foot facility for the production.
To enter the US marijuana market, Vodis announced on October 2, 2014 that it has created a wholly owned subsidiary called Vodis USA, Inc, which is based in Washington State. The subsidiary will primarily develop real estate and offer it to licensed “I-502 marijuana” businesses. Vodis also intends to license out its growing techniques and manufacturing processes, among others.
Top executives at Vodis Pharmaceuticals are CEO Otto Folprecht, President and COO Ivan Millovski, VP for Marketing Hani El Rayess, and Executive VP Penn Batanov.
Yahoo! Finance: VP News
Latest Financial News for VP